|
US2020392503A1
|
|
Methods and compositions for treatment of polycystic kidney disease
|
|
WO2020102142A1
|
|
Microrna compounds and methods for modulating mir-10b activity
|
|
TW202019441A
|
|
Methods for oral delivery of oligonucleotides
|
|
TW202016302A
|
|
Microrna compounds and methods for modulating mir-122
|
|
KR20190093207A
|
|
How to treat polycystic kidney disease
|
|
US2020165606A1
|
|
Modified Oligonucleotides for Treatment of Polycystic Kidney Disease
|
|
WO2017048770A1
|
|
Systems, compositions, and methods for formulating nucleic acid compositions
|
|
WO2017040950A1
|
|
Methods for direct measurement of microrna inhibition and mimicry
|
|
CA2995996A1
|
|
Methods for treatment of polycystic kidney disease
|
|
EP3303629A1
|
|
Non-alcoholic fatty liver disease biomarkers
|
|
WO2016022753A1
|
|
Targeting micrornas for metabolic disorders
|
|
AU2014271307A1
|
|
Targeting microRNAs for the treatment of liver cancer
|
|
WO2015061536A1
|
|
Microrna compounds and methods for modulating mir-21 activity
|
|
TN2014000401A1
|
|
Microrna compounds and methods for modulating mir-21 activity
|
|
AU2014259954A1
|
|
MicroRNA compounds and methods for modulating miR-122
|
|
US2015031130A1
|
|
Compounds and methods for enhanced cellular uptake
|
|
TW201345918A
|
|
MicroRNA (MICRORNA) compounds and methods for modulating MIR-21 activity
|
|
AU2013200489A1
|
|
Methods for use in modulating miR-122a
|
|
SG194636A1
|
|
Microrna compounds and methods for modulating mir-21 activity
|
|
WO2012145374A1
|
|
TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS
|
